Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration
- PMID: 21909804
- DOI: 10.1007/s11136-011-0003-8
Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration
Abstract
Purpose: Understand the choice of recall period for PRO measures based on intended use, characteristics of the disease, treatment, and attributes of studies.
Methods: Current practice and considerations were reviewed within several disease areas (overactive bladder, menopausal hot flashes, niacin-induced flushing, osteoarthritis pain, irritable bowel symptoms, benign prostatic hyperplasia, and alopecia).
Results: Rationales were identified for using different recall periods, including event-driven (immediate), daily, up to weekly, and longer than weekly. This work demonstrates that (1) recall depends on what the PRO measure captures, its intended use, and attributes of the disease and study; (2) within the same disease area, recall can vary depending on the concept or phenomenon of interest; (3) recall must consider patient burden and their ability to easily and accurately recall the information requested; and (4) recall must be consistent with the duration of the trial and the scheduled clinic visits.
Conclusions: Shorter recall periods may underestimate symptom burden when symptoms have diurnal or day-to-day fluctuation and may place undue burden on patients. On the other hand, recall intervals that are too long may either over- or underestimate the health state. Therefore, appropriate criteria should be considered given attributes of the disease when selecting an adequate recall period.
Similar articles
-
Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20. Clin Trials. 2017. PMID: 28545337 Free PMC article.
-
Optimal recall periods for patient-reported outcomes: challenges and potential solutions.Curr Med Res Opin. 2009 Apr;25(4):929-42. doi: 10.1185/03007990902774765. Curr Med Res Opin. 2009. PMID: 19257798
-
Shorter Recall Period for the Thyroid-Related Patient-Reported Outcome Measure ThyPRO Did Not Change the Accuracy as Evaluated by Repeated Momentary Measurements.Thyroid. 2020 Feb;30(2):185-191. doi: 10.1089/thy.2019.0380. Thyroid. 2020. PMID: 31928182
-
A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?Eur Urol. 2016 Nov;70(5):799-805. doi: 10.1016/j.eururo.2016.04.033. Epub 2016 May 6. Eur Urol. 2016. PMID: 27160948 Review.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
Cited by
-
Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ).Headache. 2018 Nov;58(10):1612-1628. doi: 10.1111/head.13420. Epub 2018 Oct 30. Headache. 2018. PMID: 30374958 Free PMC article.
-
Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ).J Patient Rep Outcomes. 2018 Sep 12;2:43. doi: 10.1186/s41687-018-0068-z. eCollection 2018 Dec. J Patient Rep Outcomes. 2018. PMID: 30294713 Free PMC article.
-
Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ).J Patient Rep Outcomes. 2018 Sep 19;2:44. doi: 10.1186/s41687-018-0064-3. eCollection 2018 Dec. J Patient Rep Outcomes. 2018. PMID: 30294714 Free PMC article.
-
Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS).J Patient Rep Outcomes. 2020 Feb 18;4(1):13. doi: 10.1186/s41687-020-0177-3. J Patient Rep Outcomes. 2020. PMID: 32072316 Free PMC article.
-
Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial.BMC Complement Altern Med. 2016 Sep 13;16(1):356. doi: 10.1186/s12906-016-1321-8. BMC Complement Altern Med. 2016. PMID: 27618916 Free PMC article. Clinical Trial.
References
MeSH terms
LinkOut - more resources
Full Text Sources